Advances in Cancer Immunotherapy™: A Focus on MSI-High and TMB-High Cancers

When:  Nov 3, 2021 from 16:00 to 20:00 (CT)
This program will be hosted virtually.


Michael Morse, MD – Duke University Medical Center
Michael Overman, MD –The University of Texas MD Anderson Cancer Center

Program Learning Objectives 

  • Identify the cancer immunotherapy approaches in use for the treatment of MSI-H/TMB-H cancers.
  • Summarize recent updates in cancer immunotherapy for MSI-H/TMB-H cancers.
  • Implement cancer immunotherapy for MSI-H/TMB-H cancer into clinical practice appropriately.
  • Describe the rationale for the use of cancer immunotherapy in MSI-H/TMB-H cancers.

For more information on the program, click below.


View the SITC Meeting Code of Conduct.